Drugs / e-ATG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03922724 | Apr 2019 → Jun 2027 expected | lymphoproliferative syndrome, peripheral T-cell lymphoma, not otherwise specified | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | e-ATG | “e-ATG 40 mg/kg/day IV on days -14 and -13, pentostatin 4 mg/m2/day IV on days -11 and -7” NCT03922724 ↗ |
| Route | Intravenous | “e-ATG 40 mg/kg/day IV on days -14 and -13” NCT03922724 ↗ |